Japan-based Towa Pharmaceutical Co., Ltd. (TSE: 4553) has agreed to acquire Tanabe Pharma Factory Co., Ltd., the manufacturing subsidiary of Tanabe Pharma Corporation, along with domestic manufacturing and marketing approvals for 17 products across 35 specifications, as Tanabe accelerates its exit from primary manufacturing in favor of a pure R&D and business development model.
Financial terms were not disclosed by mutual agreement of both parties. The transaction is structured as a 100% share transfer of Tanabe Pharma Factory — which operates the Onoda and Yoshitomi plants and reported revenue of approximately JPY 15.8 billion in FY2025 with 538 employees — to Towa Pharmaceutical. Separately, marketing and manufacturing approvals for the 17 products, which include established brands such as Urso (ursodeoxycholic acid), Depas (etizolam), and Tanatril (imidapril), will be transferred in stages beginning April 2027. Products manufactured at the Onoda and Yoshitomi plants will continue to be produced at those facilities under a contract manufacturing arrangement post-transfer. Both the share transfer, planned for end of November 2026, and the succession of marketing approvals are conditional on antitrust clearance. Notably, Tanabe Pharma's Chemistry, Manufacturing, and Control function is excluded from the transaction.
For Towa Pharmaceutical, one of Japan's largest generic drug manufacturers with FY2025 revenue of 273.7 billion yen, the acquisition adds established branded product lines and two dedicated manufacturing sites to its existing domestic production infrastructure, reinforcing its position as a core domestic supplier. For Tanabe Pharma, now privately held by Bain Capital following its 2020 delisting, the divestiture completes a structural shift away from owning manufacturing capacity — a model it has pursued consistently. Earlier this year, Tanabe completed the USD 2.5 billion sale of its Radicava (edaravone) franchise to Shionogi, its largest single asset divestiture, which established Shionogi as a commercial rare disease company in the US while freeing Tanabe from its most significant commercial obligation. The Towa transaction follows the same strategic logic: monetizing operating assets to concentrate capital on R&D and licensing activity. Together, these moves suggest Tanabe is repositioning as a leaner, externally-oriented drug developer rather than an integrated pharmaceutical manufacturer — a model that reduces fixed costs but increases dependence on partners for supply chain continuity.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Spot something wrong? Report an issue with this article